Publications by authors named "A H Maki"
Ruxolitinib, a Janus kinase (JAK1-JAK2) inhibitor, has demonstrated safety and efficacy in patients with graft-versus-host disease (GvHD). This phase 3 randomized trial (REACH3) evaluated the efficacy and the safety of ruxolitinib 10 mg twice daily compared with investigator-selected best available therapy (BAT) in a subgroup of Japanese patients (n = 37) with steroid-refractory or dependent (SR/D) chronic GvHD. At data cut-off, treatment was ongoing in 17 patients and discontinued in 20.
View Article and Find Full Text PDFDeveloping microphysiological cell culture platforms with a three-dimensional (3D) microenvironment has been a significant advancement from traditional monolayer cultures. Still, most of the current microphysiological platforms are limited in closed designs, i.e.
View Article and Find Full Text PDFArticle Synopsis
- Solitary fibrous tumor (SFT) is a type of spindle cell tumor linked to a specific genetic fusion (NAB2-STAT6) that can occur in any soft tissue, though pancreatic cases are rare.
- A 36-year-old man experienced abdominal pain and was found to have a mass in the pancreatic tail, but a biopsy did not confirm the diagnosis, leading to potential confusion with other pancreatic tumors.
- After robotic surgery to remove the tumor, the histopathology showed spindle cells, and specific immunostains confirmed SFT with a low chance of spreading, highlighting the effectiveness of robotic surgery for treatment.
Littering of cigarette butts is a major environmental challenge. In 2022, ~124 billion cigarette butts were littered in the United States. This litter may pose an environmental justice concern by disproportionately affecting human and environmental health in communities of color or communities of low socioeconomic status.
View Article and Find Full Text PDFBackground: We aimed to investigate the patterns of incidence and prevalence of bone sarcoma (BS) and soft tissue sarcoma (STS), morphology as well as geographical distribution in the elderly in Iran.
Methods: By the primary site of the tumor and the morphological types, whole cases of cancer were classified. Then, the WHO classification (2018) and the third revision of the standard International Classification of Diseases for Oncology (ICD-O-3) were used to assign a code to them.